N‐Substituted piperazine‐coupled imidazo[2,1‐b]thiazoles as inhibitors of Mycobacterium tuberculosis: Synthesis, evaluation, and docking studies

Abstract

AbstractAn innovative series of N‐substituted piperazine‐linked imidazothiazole derivatives 7(a–x) were synthesized, and their antitubercular effectiveness was evaluated. A three‐step reaction sequence involving the condensation of 1,3‐dichloroacetone and thiourea, coupling with substituted piperazines to give the intermediates 5(a–d) and cyclization with substituted α‐bromoacetophenones produced the desired imidazothiazole derivatives 7(a–x) in excellent yields. In vitro screening of new derivatives against Mycobacterium tuberculosis H37Rv resulted in 7k (minimum inhibitory concentration [MIC]: 0.78 μg/mL) and 7g and 7h (MIC: 1.56 μg/mL) as potent hit compounds. Further, the docking studies of the promising compounds 7k, 7g, and 7h revealed that the best molecular interactions are with the DprE1 in complex with sulfonyl PBTZ of M. tuberculosis as the target protein (PDB ID: 6G83).